Biochemical Modulation of Arabinosylcytosine for Therapy of Leukemias

References

• Keating M. J., McCredie K. B., Bodey G. P., et al. Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA 1982; 248: 2481–2486
   PubMed Web of Science ®Google Scholar
• Chu M. Y., Fischer G. A. Comparative studies of leukemia cells sensitive and resistant to cytosine arabi-noside. Biochem. Pharmacol. 1965; 14: 333–341
   PubMed Web of Science ®Google Scholar
• Schrecker A. W., Urshel M. J. Metabolism of l-β-D-arabinofuranosylcytosine in leukemia L1210: studies with intact cells. Cancer Res. 1968; 28: 793–801
   PubMed Web of Science ®Google Scholar
• Kessel D., Hall T. C., Wodinsky I. Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science 1967; 156: 1240–1241
   PubMed Web of Science ®Google Scholar
• Momparler R. L., Brent T. P., Labitan A., et al. Studies on the phosphorylation of cytosine arabinoside in mammalian cells. Mol. Pharmacol. 1971; 7: 413–419
   PubMed Web of Science ®Google Scholar
• Liliemark J. O., Plunkett W. Regulation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate accumulation in human leukemia cells by deoxycytidine 5′-triphosphate. Cancer Res. 1986; 46: 1079–1083
   PubMed Web of Science ®Google Scholar
• Fram R., Major P., Egan E., et al. A Phase I-II study of combination therapy with thymidine and cytosine arabinoside. Cancer Chemother. Pharmacol. 1983; 11: 43–47
   PubMed Web of Science ®Google Scholar
• Zittoun R., Zittoun J., Marquet J., et al. Modulation of 1-β-D-arabinofuranosylcytosine metabolism by thymidine in human acute leukemia. Cancer Res. 1985; 45: 5186–5192
   PubMed Web of Science ®Google Scholar
• Schilsky R. L., Williams S. F., Ultmann J. E. Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 1987; 5: 419–425
   PubMed Web of Science ®Google Scholar
• Griffig J., Koob R., Blakley R. L. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastoid cells. Cancer Res. 1989; 49: 6923–6928
   PubMed Web of Science ®Google Scholar
• Tseng W-C., Derse D., Chang Y-C. In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroaden-ine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol. Pharmacol. 1982; 21: 474–477
   PubMed Web of Science ®Google Scholar
• Heinemann V., Xu Y-Z., Chubb S., et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-2′-difluorodeoxycytidine. Mol. Pharmacol. 1990; 38: 567–572
   PubMed Web of Science ®Google Scholar
• Gandhi V., Plunkett W. Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cy-totoxicity of arabinosyl nucleosides. Cancer Res. 1990; 50: 3675–3680
   PubMed Web of Science ®Google Scholar
• Carter G. L., Cory J. G. Cross resistance patterns in hydroxyurea-resistant leukemia L1210 cells. Cancer Res. 1988; 48: 5796–5799
   PubMed Web of Science ®Google Scholar
• Gandhi V., Plunkett W. Modulation of arabinosyl nucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988; 48: 329–334
   PubMed Web of Science ®Google Scholar
• Plunkett W., Liliemark J. O., Adams T. M., et al. Saturation of l-β-D-arabinosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabi-nosylcytosine therapy. Cancer Res. 1987; 47: 3005–3011
   PubMed Web of Science ®Google Scholar
• Plunkett W., Liliemark J. O., Estey E., et al. Saturation of ara-CTP accumulation during high-dose ara-C therapy. Pharmacologic rationale for intermediate-dose ara-C. Sem. Oncol. 1987; 14(Suppl 1)159–166
   PubMedGoogle Scholar
• Estey E., Plunkett W., Kantarjian H., et al. Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): Confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Leukemia Lymphoma 1993, in press
   Google Scholar
• Hiddemann W. Cytosine arabinoside in the treatment of acute myeloid leukemia: The role and place of high-dose regimens. Ann. Hematol. 1991; 62: 119–128
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Estey E. H., Plunkett W., et al. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am. J. Med. 1986; 81: 387–394
   PubMed Web of Science ®Google Scholar
• Spriggs D. R., Stopa E., Mayer R. J., et al. Flu-darabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res. 1986; 46: 5953–5958
   PubMed Web of Science ®Google Scholar
• Warrell R. P., Berman E. Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol. 1986; 4: 74–79
   PubMed Web of Science ®Google Scholar
• Keating M. J., Kantarjian H., Talpaz M., et al. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
   PubMed Web of Science ®Google Scholar
• Keating M. J., Kantarjian H., O'Brien S., et al. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. 1991; 9: 44–49
   PubMed Web of Science ®Google Scholar
• Danhauser L., Plunkett W., Keating M., et al. 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother. Pharmacol. 1986; 18: 145–152
   PubMed Web of Science ®Google Scholar
• Gandhi V., Nowak B., Keating M. J., et al. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: Implications for combination therapy. Blood 1989; 74: 2070–2075
   PubMed Web of Science ®Google Scholar
• Gandhi V., Kemena A., Keating M. J., et al. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992; 52: 897–903
   PubMed Web of Science ®Google Scholar
• Gandhi V., Estey E., Keating M. J., et al. Fludarabine potentiates the metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol. 1993; 11: 116–124
   PubMed Web of Science ®Google Scholar
• Cohen A., Barankiewicz J., Lederman H. M., et al. Purine and pyrimidine metabolism in human T lymphocytes: regulation of deoxyribonucleotide metabolism. J. Biol. Chem. 1980; 258: 12334–12340
   Google Scholar
• Estey E., Plunkett W., Gandhi V., et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leukemia Lymphoma 1993, in press
   Web of Science ®Google Scholar